MAIA Current Deferred Revenue vs Net Working Capital Analysis

MAIA Stock

USD 2.00 0.01 0.50%

MAIA Biotechnology financial indicator trend analysis is infinitely more than just investigating MAIA Biotechnology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether MAIA Biotechnology is a good investment. Please check the relationship between MAIA Biotechnology Current Deferred Revenue and its Net Working Capital accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MAIA Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.

Current Deferred Revenue vs Net Working Capital

Current Deferred Revenue vs Net Working Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of MAIA Biotechnology Current Deferred Revenue account and Net Working Capital. At this time, the significance of the direction appears to have strong relationship.

The correlation between MAIA Biotechnology's Current Deferred Revenue and Net Working Capital is 0.78. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of MAIA Biotechnology, assuming nothing else is changed. The correlation between historical values of MAIA Biotechnology's Current Deferred Revenue and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of MAIA Biotechnology are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Current Deferred Revenue i.e., MAIA Biotechnology's Current Deferred Revenue and Net Working Capital go up and down completely randomly.

Correlation Coefficient

0.78

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Net Working Capital

Most indicators from MAIA Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into MAIA Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MAIA Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.As of December 15, 2024, Selling General Administrative is expected to decline to about 6.6 M. In addition to that, Issuance Of Capital Stock is expected to decline to about 8.6 M

MAIA Biotechnology fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Long Term Debt	Net Invested Capital	Short Long Term Debt	Capital Stock	Non Current Liabilities Other
Total Assets		0.76	0.71	0.78	0.88	0.76	0.92	0.77	-1.0	-0.77	0.87	1.0	1.0	0.08	0.56	0.81	0.88	0.65	1.0	0.91	0.74	-0.37	0.96	-0.37	0.74	-0.37
Short Long Term Debt Total	0.76		0.91	0.9	0.49	1.0	0.69	0.95	-0.73	-0.77	0.82	0.76	0.76	0.29	0.69	0.72	0.84	0.74	0.76	0.81	0.76	-0.36	0.72	-0.36	0.75	-0.36
Other Current Liab	0.71	0.91		0.99	0.33	0.91	0.79	0.91	-0.71	-0.93	0.92	0.71	0.71	0.53	0.83	0.78	0.94	0.91	0.72	0.87	0.94	-0.6	0.56	-0.6	0.94	-0.6
Total Current Liabilities	0.78	0.9	0.99		0.42	0.9	0.85	0.9	-0.77	-0.94	0.96	0.78	0.78	0.53	0.83	0.8	0.97	0.91	0.79	0.91	0.96	-0.6	0.63	-0.6	0.96	-0.6
Total Stockholder Equity	0.88	0.49	0.33	0.42		0.49	0.67	0.43	-0.87	-0.38	0.59	0.88	0.88	-0.3	0.13	0.6	0.59	0.21	0.87	0.6	0.4	0.05	0.95	0.05	0.38	0.05
Other Liab	0.76	1.0	0.91	0.9	0.49		0.69	0.95	-0.73	-0.77	0.82	0.76	0.76	0.29	0.7	0.72	0.85	0.74	0.76	0.81	0.76	-0.36	0.72	-0.36	0.75	-0.36
Net Tangible Assets	0.92	0.69	0.79	0.85	0.67	0.69		0.78	-0.94	-0.92	0.94	0.92	0.92	0.41	0.78	0.75	0.93	0.84	0.92	0.98	0.86	-0.67	0.77	-0.67	0.88	-0.67
Current Deferred Revenue	0.77	0.95	0.91	0.9	0.43	0.95	0.78		-0.76	-0.87	0.82	0.77	0.77	0.38	0.83	0.72	0.85	0.88	0.77	0.89	0.77	-0.6	0.68	-0.6	0.79	-0.6
Net Debt	-1.0	-0.73	-0.71	-0.77	-0.87	-0.73	-0.94	-0.76		0.78	-0.88	-1.0	-1.0	-0.11	-0.58	-0.8	-0.88	-0.66	-1.0	-0.92	-0.75	0.41	-0.94	0.41	-0.75	0.41
Retained Earnings	-0.77	-0.77	-0.93	-0.94	-0.38	-0.77	-0.92	-0.87	0.78		-0.93	-0.77	-0.77	-0.58	-0.91	-0.78	-0.94	-0.98	-0.78	-0.96	-0.93	0.81	-0.57	0.81	-0.96	0.81
Accounts Payable	0.87	0.82	0.92	0.96	0.59	0.82	0.94	0.82	-0.88	-0.93		0.88	0.88	0.49	0.78	0.8	1.0	0.85	0.88	0.94	0.97	-0.56	0.73	-0.56	0.97	-0.56
Cash	1.0	0.76	0.71	0.78	0.88	0.76	0.92	0.77	-1.0	-0.77	0.88		1.0	0.09	0.56	0.8	0.88	0.65	1.0	0.91	0.74	-0.37	0.96	-0.37	0.75	-0.37
Cash And Short Term Investments	1.0	0.76	0.71	0.78	0.88	0.76	0.92	0.77	-1.0	-0.77	0.88	1.0		0.09	0.56	0.8	0.88	0.65	1.0	0.91	0.74	-0.37	0.96	-0.37	0.75	-0.37
Common Stock Shares Outstanding	0.08	0.29	0.53	0.53	-0.3	0.29	0.41	0.38	-0.11	-0.58	0.49	0.09	0.09		0.79	0.0	0.44	0.67	0.09	0.44	0.61	-0.72	-0.15	-0.72	0.62	-0.72
Non Current Liabilities Total	0.56	0.69	0.83	0.83	0.13	0.7	0.78	0.83	-0.58	-0.91	0.78	0.56	0.56	0.79		0.46	0.77	0.96	0.56	0.85	0.8	-0.89	0.36	-0.89	0.83	-0.89
Other Current Assets	0.81	0.72	0.78	0.8	0.6	0.72	0.75	0.72	-0.8	-0.78	0.8	0.8	0.8	0.0	0.46		0.85	0.68	0.83	0.77	0.76	-0.37	0.72	-0.37	0.76	-0.37
Other Stockholder Equity	0.88	0.84	0.94	0.97	0.59	0.85	0.93	0.85	-0.88	-0.94	1.0	0.88	0.88	0.44	0.77	0.85		0.86	0.89	0.95	0.97	-0.56	0.74	-0.56	0.97	-0.56
Total Liab	0.65	0.74	0.91	0.91	0.21	0.74	0.84	0.88	-0.66	-0.98	0.85	0.65	0.65	0.67	0.96	0.68	0.86		0.66	0.9	0.88	-0.87	0.44	-0.87	0.91	-0.87
Total Current Assets	1.0	0.76	0.72	0.79	0.87	0.76	0.92	0.77	-1.0	-0.78	0.88	1.0	1.0	0.09	0.56	0.83	0.89	0.66		0.91	0.76	-0.38	0.95	-0.38	0.76	-0.38
Short Term Debt	0.91	0.81	0.87	0.91	0.6	0.81	0.98	0.89	-0.92	-0.96	0.94	0.91	0.91	0.44	0.85	0.77	0.95	0.9	0.91		0.88	-0.7	0.77	-0.7	0.9	-0.7
Common Stock	0.74	0.76	0.94	0.96	0.4	0.76	0.86	0.77	-0.75	-0.93	0.97	0.74	0.74	0.61	0.8	0.76	0.97	0.88	0.76	0.88		-0.62	0.55	-0.62	1.0	-0.62
Long Term Debt	-0.37	-0.36	-0.6	-0.6	0.05	-0.36	-0.67	-0.6	0.41	0.81	-0.56	-0.37	-0.37	-0.72	-0.89	-0.37	-0.56	-0.87	-0.38	-0.7	-0.62		-0.12	1.0	-0.67	1.0
Net Invested Capital	0.96	0.72	0.56	0.63	0.95	0.72	0.77	0.68	-0.94	-0.57	0.73	0.96	0.96	-0.15	0.36	0.72	0.74	0.44	0.95	0.77	0.55	-0.12		-0.12	0.55	-0.12
Short Long Term Debt	-0.37	-0.36	-0.6	-0.6	0.05	-0.36	-0.67	-0.6	0.41	0.81	-0.56	-0.37	-0.37	-0.72	-0.89	-0.37	-0.56	-0.87	-0.38	-0.7	-0.62	1.0	-0.12		-0.67	1.0
Capital Stock	0.74	0.75	0.94	0.96	0.38	0.75	0.88	0.79	-0.75	-0.96	0.97	0.75	0.75	0.62	0.83	0.76	0.97	0.91	0.76	0.9	1.0	-0.67	0.55	-0.67		-0.67
Non Current Liabilities Other	-0.37	-0.36	-0.6	-0.6	0.05	-0.36	-0.67	-0.6	0.41	0.81	-0.56	-0.37	-0.37	-0.72	-0.89	-0.37	-0.56	-0.87	-0.38	-0.7	-0.62	1.0	-0.12	1.0	-0.67

Click cells to compare fundamentals

MAIA Biotechnology Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether MAIA Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of MAIA Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maia Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maia Biotechnology Stock:

How To Invest In MAIA

Details

Is MAIA Stock a good investment?

Details

What is MAIA Biotechnology's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MAIA Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.

You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MAIA Biotechnology. If investors know MAIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MAIA Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.34)

Return On Assets

(1.07)

Return On Equity

(5.60)

The market value of MAIA Biotechnology is measured differently than its book value, which is the value of MAIA that is recorded on the company's balance sheet. Investors also form their own opinion of MAIA Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is MAIA Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MAIA Biotechnology's market value can be influenced by many factors that don't directly affect MAIA Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between MAIA Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if MAIA Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MAIA Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

MAIA Current Deferred Revenue vs Net Working Capital Analysis

Current Deferred Revenue vs Net Working Capital

Current Deferred Revenue vs Net Working Capital Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Net Working Capital

MAIA Biotechnology fundamental ratios Correlations

MAIA Biotechnology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Other Liab	+ 1.0	Short Long Term Debt Total
Other Stockholder Equity	+ 1.0	Accounts Payable
Cash And Short Term Investments	+ 1.0	Cash

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Assets
Total Liab	- 0.98	Retained Earnings
Capital Stock	- 0.96	Retained Earnings